Cargando…
Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
Checkpoint inhibitors (CPI) represent a novel therapeutical strategy with a high efficacy both in solid and hematological cancers. They act by reactivating the immune system against neoplastic cells but may, in turn, cause immune-related adverse events (IRAEs) involving several organs with variable...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143083/ https://www.ncbi.nlm.nih.gov/pubmed/35631383 http://dx.doi.org/10.3390/ph15050557 |